Search results for "TYROSINE KINASE"

showing 10 items of 362 documents

Multiple Ig-like featuring genes divergent within and among individuals of the marine sponge Geodia cydonium.

1998

Abstract The receptor tyrosine kinase of the marine sponge Geodia cydonium features two extracellular Ig-like domains in which we recently documented RT-PCR polymorphism among individuals. Genomic-PCR analysis presented here revealed 14 unique sequences from four sponges, differing predominantly in the sequence of an intron which splits the Ig-like domains. Nevertheless, analysis of putative coding regions in 19 distinct clones (156–159 aa) from seven sponges revealed 69 positions of nucleotide substitutions, 67.6% of them non-synonymous, translating into 43 positions of divergent residues. Excluding aa deletions, these 19 sequences share pairwise aa identities of 89–99%. In three sponges, …

Molecular Sequence DataImmunoglobulinsGenomePolymerase Chain ReactionReceptor tyrosine kinaselaw.inventionlawMHC class IGeneticsCoding regionAnimalsHumansAmino Acid SequenceGenePolymerase chain reactionGeneticsPolymorphism GeneticbiologyBase SequenceSequence Homology Amino AcidIntronReceptor Protein-Tyrosine KinasesGeneral MedicineDNAbiology.organism_classificationIntronsPoriferaSpongeMultigene Familybiology.proteinSequence AlignmentGene
researchProduct

2014

Oligodendrocytes are the myelinating glial cells of the central nervous system. In the course of brain development, oligodendrocyte precursor cells migrate, scan the environment and differentiate into mature oligodendrocytes with multiple cellular processes which recognize and ensheath neuronal axons. During differentiation, oligodendrocytes undergo dramatic morphological changes requiring cytoskeletal rearrangements which need to be tightly regulated. The non-receptor tyrosine kinase Fyn plays a central role in oligodendrocyte differentiation and myelination. In order to improve our understanding of the role of oligodendroglial Fyn kinase, we have identified Fyn targets in these cells. Pur…

MultidisciplinarybiologyIntegrinCellOligodendrocyte differentiationCell migrationTransfectionOligodendrocyteCell biologymedicine.anatomical_structureFYNmedicinebiology.proteinTyrosine kinasePLOS ONE
researchProduct

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor

2009

Abstract In acute myeloid leukemia (AML), internal tandem duplications (ITDs) of the juxtamembrane (JM) of FLT3 have been shown to play a crucial role in driving proliferation and survival of the leukemic clone. Here, we report the identification of FLT3_ITD mutations located in non-JM domains of the FLT3-receptor. This novel type of FLT3_ITD mutation was found in 216 of 753 (28.7%) of unselected FLT3_ITD-positive AML cases. An FLT3 receptor harbouring a prototypic non-JM ITD (FLT3_ITD627E) mediated constitutive phosphorylation of FLT3 and of STAT5, suggesting that non-JM ITDs confer constitutive activation of the receptor. FLT3_ITD627E induced transformation of hematopoietic 32D cells and …

MutationImmunologyClone (cell biology)MedizinMyeloid leukemiaCell BiologyHematologyBiologymedicine.disease_causeBiochemistryMolecular biologyReceptor tyrosine kinasehemic and lymphatic diseasesTrk receptormedicinebiology.proteinPhosphorylationReceptorSTAT5
researchProduct

A Comprehensive Tissue Microarray-Based FISH Screen of ALK Gene in Neuroblastomas

2011

The heterogeneity of neuroblastic tumors added to the immense biological complexity has led to an unprecedented scale of investigations and a growing list of molecular genetic targets for prognosis as well as therapy. Recently, Anaplastic Lymphoma Kinase (ALK) has been identified as a major predisposing gene as well as a potential therapeutic target for neuroblastoma. Individuals with ALK-related neuroblastoma susceptibility (i.e., heterozygous for an ALK mutation) are at risk of developing neuroblastic tumors. Aberrant copy number or mutations in ALK gene and overexpression of its protein tyrosine-kinase receptor have been related to poor prognosis of this disease, although a great degree …

MutationTissue microarraymedicine.diagnostic_testBiologymedicine.disease_causemedicine.diseaseNeuroblastic Tumorhemic and lymphatic diseasesNeuroblastomamedicineCancer researchAnaplastic lymphoma kinaseGeneTyrosine kinaseFluorescence in situ hybridization
researchProduct

SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia

2014

SIRT1 is an important regulator of cellular stress response and genomic integrity. Its role in tumorigenesis is controversial. Whereas sirtuin 1 (SIRT1) can act as a tumor suppressor in some solid tumors, increased expression has been demonstrated in many cancers, including hematologic malignancies. In chronic myeloid leukemia, SIRT1 promoted leukemia development, and targeting SIRT1 sensitized chronic myeloid leukemia progenitors to tyrosine kinase inhibitor treatment. In this study, we investigated the role of SIRT1 in acute myeloid leukemia (AML). We show that SIRT1 protein, but not RNA levels, is overexpressed in AML samples harboring activating mutations in signaling pathways. In FMS-l…

Myeloidendocrine system diseasesmedicine.drug_classImmunologyBiologymedicine.disease_causeBiochemistryTyrosine-kinase inhibitorMiceSirtuin 1hemic and lymphatic diseasesmedicineAnimalsHumansGene Knock-In TechniquesKinase activityfood and beveragesMyeloid leukemiaCell BiologyHematologymedicine.diseaseEnzyme ActivationMice Inbred C57BLLeukemia Myeloid Acuteenzymes and coenzymes (carbohydrates)Leukemiamedicine.anatomical_structureGene Knockdown TechniquesCancer researchHeterograftsTumor Suppressor Protein p53Signal transductionCarcinogenesisTyrosine kinasehormones hormone substitutes and hormone antagonistsDNA DamageSignal TransductionBlood
researchProduct

Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition

2020

Abstract The interaction of menin (MEN1) and MLL (MLL1, KMT2A) is a dependency and provides a potential opportunity for treatment of NPM1-mutant (NPM1mut) and MLL-rearranged (MLL-r) leukemias. Concomitant activating driver mutations in the gene encoding the tyrosine kinase FLT3 occur in both leukemias and are particularly common in the NPM1mut subtype. In this study, transcriptional profiling after pharmacological inhibition of the menin-MLL complex revealed specific changes in gene expression, with downregulation of the MEIS1 transcription factor and its transcriptional target gene FLT3 being the most pronounced. Combining menin-MLL inhibition with specific small-molecule kinase inhibitors…

NPM1Transcription GeneticImmunologyApoptosisBiochemistryMiceRandom AllocationMice Inbred NODCell Line TumorProto-Oncogene Proteinshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsGene expressionmedicineAnimalsHumansMEN1PhosphorylationMyeloid Ecotropic Viral Integration Site 1 ProteinProtein Kinase InhibitorsneoplasmsbiologyGene Expression Regulation LeukemicKinaseNuclear ProteinsMyeloid leukemiaDrug SynergismHistone-Lysine N-MethyltransferaseCell BiologyHematologymedicine.diseaseCoculture TechniquesNeoplasm ProteinsLeukemia Myeloid AcuteLeukemiaKMT2Afms-Like Tyrosine Kinase 3biology.proteinCancer researchNucleophosminProtein Processing Post-TranslationalTyrosine kinaseMyeloid-Lymphoid Leukemia ProteinBlood
researchProduct

Sensing life: regulation of sensory neuron survival by neurotrophins

2002

Neurotrophins are a family of structurally and functionally related neurotrophic factors which, in mammals, include: nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3 (NT-3), and NT-4/5. In addition to their canonical role in promoting neuronal survival, these molecules appear to regulate multiple aspects of the development of the nervous system in vertebrates, including neuronal differentiation, axon elongation and target innervation, among others. Actions of neurotrophins and of their receptors in vivo are being analyzed by loss-of-function or gain-of-function experiments in mice. Here, we review the phenotypes of the primary sensory system in these mutant mouse strai…

Nervous systemGenetically modified mouseCell SurvivalMice TransgenicSensory systemReceptors Nerve Growth FactorMiceCellular and Molecular NeuroscienceNeurotrophic factorsmedicineAnimalsReceptor trkCNerve Growth FactorsNeurons AfferentAxonMolecular BiologyMice KnockoutPharmacologyMembrane GlycoproteinsbiologyBrain-Derived Neurotrophic FactorCell BiologyAnatomyProtein-Tyrosine KinasesSensory neuronmedicine.anatomical_structureNerve growth factornervous systembiology.proteinMolecular MedicineNeuroscienceSignal TransductionNeurotrophinCellular and Molecular Life Sciences
researchProduct

IRS2 signalling is required for the development of a subset of sensory spinal neurons

2012

Insulin and insulin-like growth factor-I play important roles in the development and maintenance of neurons and glial cells of the nervous system. Both factors activate tyrosine kinase receptors, which signal through adapter proteins of the insulin receptor substrate (IRS) family. Although insulin and insulin-like growth factor-I receptors are expressed in dorsal root ganglia (DRG), the function of IRS-mediated signalling in these structures has not been studied. Here we address the role of IRS2-mediated signalling in murine DRG. Studies in cultured DRG neurons from different embryonic stages indicated that a subset of nerve growth factor-responsive neurons is also dependent on insulin for …

Nervous systemmedicine.medical_specialtybiologyGeneral NeuroscienceInsulinmedicine.medical_treatmentGrowth factorReceptor tyrosine kinaseIRS2Insulin-like growth factorEndocrinologymedicine.anatomical_structurenervous systemInternal medicineInsulin receptor substratebiology.proteinmedicineReceptorEuropean Journal of Neuroscience
researchProduct

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

2008

AbstractThe tyrosine kinase inhibitors sorafenib and sunitinib are approved for the treatment of patients with malignant diseases. To analyze the possible use of these compounds in combination with immunotherapeutic approaches, we analyzed the effects of both inhibitors on the immunostimulatory capacity of human dendritic cells (DCs) and the induction of primary immune responses in vivo. Sorafenib, but not sunitinib, inhibits function of DCs, characterized by reduced secretion of cytokines and expression of CD1a, major histocompatibility complex, and costimulatory molecules in response to TLR ligands as well as by their impaired ability to migrate and stimulate T-cell responses. These inhib…

NiacinamideSorafenibIndolesPyridinesImmunologyAntineoplastic AgentsApoptosisCD8-Positive T-LymphocytesPharmacologyBiologyurologic and male genital diseasesMajor histocompatibility complexT-Lymphocytes RegulatoryBiochemistryPeripheral blood mononuclear cellMiceImmune systemCell MovementIn vivoSunitinibmedicineAnimalsHumansCytotoxic T cellPyrrolesCells CulturedSunitinibPhenylurea CompoundsBenzenesulfonatesGranulocyte-Macrophage Colony-Stimulating FactorDextransDendritic CellsCell BiologyHematologySorafenibEndocytosisfemale genital diseases and pregnancy complicationsMice Inbred C57BLToll-Like Receptor 4biology.proteinCytokinesFemaleInterleukin-4Lymphocyte Culture Test MixedTyrosine kinaseCell DivisionSignal Transductionmedicine.drugBlood
researchProduct

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.

2021

We have analyzed treatment patterns and outcomes of relapsed/refractory(R/R) FLT3mut AML adult patients registered in our institutional data base between 1998 and 2018. Overall, 147 patients were evaluable: 34 from 1998 to 2009, 113 from 2010 to 2018. Salvage treatments were intensive chemotherapy ( n = 25, 74%), and supportive care ( n = 9, 26%) in the 1998-2009 period, and intensive chemotherapy ( n = 63, 56%), hypomethylating agent ( n = 7, 6%), low-dose cytarabine-based ( n = 8, 7%), clinical trial ( n = 16, 14%) and supportive care ( n = 19, 17%) in the 2010-2018 period. Complete remission (CR) or with incomplete recovery (CRi) rate was 44%, 49% among patients treated intensively (vs 3…

OncologyAdultCancer Researchmedicine.medical_specialtyreal-world*real-world03 medical and health sciences0302 clinical medicineRefractoryInternal medicineAntineoplastic Combined Chemotherapy Protocolsmedicine*FLT3mut AMLHumansPatterns of carerelapseSalvage TherapyAdult patientsFLT3mut AMLbusiness.industryFLT3mut AML real-world relapse/refractoryRemission InductionCytarabineMyeloid leukemiaHematology*relapse/refractoryrefractoryLeukemia Myeloid AcuteTreatment OutcomeOncologyfms-Like Tyrosine Kinase 3030220 oncology & carcinogenesisRelapsed refractorybusiness030215 immunologyLeukemialymphoma
researchProduct